STONY BROOK, N.Y.—CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary, has announced that patient recruitment for its Phase 2a clinical trial for heart failure has been expanded to Stony Brook University’s Heart Institute. The study is seeking to determine if the stem cell properties of CardioCell’s ischemia-tolerant mesenchymal stem cells (itMSCs) can cause a patient’s own cardiomyocytes to improve their ability to contract, which could improve or restore heart function.

 

“The Heart Institute of Stony Brook University Medical Center is ideally suited for CardioCell’s chronic HF study,” says Dr. Sergey Sikora, CardioCell’s president and CEO. “The hospital delivers superior cardiovascular care to all of Long Island and surrounding areas, and its state-of the-art labs are staffed by experts at handling live cells like the itMSCs used in this study’s protocols.”